# Brain capillary endothelial-like cells show altered barrier functionality and reduced transport of amyloid β in late-onset Alzheimer disease

**Authors:** Carla Hartmann, Undine Haferkamp, Antje Appelt-Menzel, Janica Barenberg, Andreas Brachner, Toni Ehrhard, Julia Feldhaus, Anna Gerhartl, Thomas Hollemann, Linda Anna Michelle Kulka, Selin Leckzik, Jennifer Leu, Marcel Seungsu Woo, Manuel Alexander Friese, Alzheimer’s Disease Neuroimaging Initiative, Marco Metzger, Winfried Neuhaus, Sabrina Oerter, Heidi Olzscha, Andreas Pich, Dagmar Riemann, Ole Pless, Dan Rujescu, Matthias Jung

PMC · DOI: 10.1186/s12987-025-00753-7 · 2026-01-22

## TL;DR

This study shows that brain capillary cells in late-onset Alzheimer's disease have altered barrier function and reduced transport of harmful amyloid beta oligomers.

## Contribution

A novel in vitro model using patient-derived stem cells reveals LOAD-specific changes in blood-brain barrier function and amyloid transport.

## Key findings

- LOAD BCECs show subtle changes in barrier integrity markers like mucins and aquaporins.
- LOAD BCECs exhibit reduced levels of cadherin 5 and altered transport of Aβ oligomers.
- Findings were validated in cerebrospinal fluid proteomes of LOAD patients.

## Abstract

With the progression of late-onset Alzheimer disease (LOAD), there is a dysregulation and then a breakdown of the blood-brain barrier (BBB). An important pathological feature in the brains of patients is the accumulation of amyloid beta (Aβ) peptides. Their aggregation leads to the formation of particularly harmful Aβ oligomers (Aβ-O). Unfortunately, our understanding of changes in the blood-brain barrier, particularly with regard to the effects of Aβ-O, is still very limited.

This study investigated a LOAD-specific and induced pluripotent stem cell (hiPSC)-based in vitro model of the BBB for disease mechanisms and validated the findings in two independent laboratories. This study also investigated Aβ transport across the BBB. Furthermore, obtained in vitro findings were confirmed in the cerebrospinal fluid proteome of a LOAD patient cohort.

Control and LOAD hiPSCs exhibited comparable efficiency in forming brain capillary endothelial-like cells (BCECs). Although transendothelial electrical resistance (TEER) assessments indicated no significant differences in barrier tightness between LOAD and control BCECs, high-throughput multiplex qPCR analysis revealed subtle alterations in barrier integrity. This included changes in various barrier markers, such as mucins (MUC1, MUC20), aquaporins (AQP5, AQP10), junctional transcripts (CLDNs, TJP1, OCLN), and receptors (LRP1, INSR, LSR), which were confirmed in LOAD patients. High-content imaging and flow cytometry indicated reduced cadherin 5 (CDH5) levels in LOAD BCECs. Importantly, the results also highlighted a difference in the transport of Aβ-O across the BBB.

This model demonstrates a LOAD-relevant phenotype with decreased Aβ transport and alterations in key transcripts and could thus serve for future translational studies to rescue pathogenic phenotypes.

The online version contains supplementary material available at 10.1186/s12987-025-00753-7.

## Linked entities

- **Genes:** MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582], MUC20 (mucin 20, cell surface associated) [NCBI Gene 200958], AQP5 (aquaporin 5) [NCBI Gene 362], AQP10 (aquaporin 10) [NCBI Gene 89872], TJP1 (tight junction protein 1) [NCBI Gene 7082], OCLN (occludin) [NCBI Gene 100506658], LRP1 (LDL receptor related protein 1) [NCBI Gene 4035], INSR (insulin receptor) [NCBI Gene 3643], LSR (lipolysis stimulated lipoprotein receptor) [NCBI Gene 51599], CDH5 (cadherin 5) [NCBI Gene 1003]
- **Proteins:** ab (abrupt), ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase), CDH5 (cadherin 5)
- **Diseases:** Alzheimer disease (MONDO:0004975), late-onset Alzheimer disease (MONDO:0007089)

## Full-text entities

- **Genes:** HLA-G (major histocompatibility complex, class I, G) [NCBI Gene 3135] {aka MHC-G}, TJP2 (tight junction protein 2) [NCBI Gene 9414] {aka C9DUPq21.11, DFNA51, DUP9q21.11, FHCA1, PFIC4, X104}, NES (nestin) [NCBI Gene 10763] {aka Nbla00170}, Tjp1 (tight junction protein 1) [NCBI Gene 21872] {aka ZO1}, WWC2 (WW and C2 domain containing 2) [NCBI Gene 80014] {aka BOMB}, SLC7A5 (solute carrier family 7 member 5) [NCBI Gene 8140] {aka 4F2LC, CD98, D16S469E, E16, LAT1, MPE16}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, GDNF (glial cell derived neurotrophic factor) [NCBI Gene 2668] {aka ATF, ATF1, ATF2, HFB1-GDNF, HSCR3}, Jam2 (junction adhesion molecule 2) [NCBI Gene 67374] {aka 1110002N23Rik, 2410030G21Rik, 2410167M24Rik, JAM-2, JAM-B, Jcam2}, ABCC4 (ATP binding cassette subfamily C member 4 (PEL blood group)) [NCBI Gene 10257] {aka MOAT-B, MOATB, MRP4}, MUC20 (mucin 20, cell surface associated) [NCBI Gene 200958] {aka MUC-20}, CLDN17 (claudin 17) [NCBI Gene 26285], INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}, PAX6 (paired box 6) [NCBI Gene 5080] {aka AN, AN1, AN2, ASGD5, D11S812E, FVH1}, Lrp1 (low density lipoprotein receptor-related protein 1) [NCBI Gene 16971] {aka A2mr, CD91, Lrp, b2b1554Clo}, CLDN7 (claudin 7) [NCBI Gene 1366] {aka CEPTRL2, CLDN-7, CPETRL2, Hs.84359, claudin-1}, Cldn23 (claudin 23) [NCBI Gene 71908] {aka 2310014B08Rik}, DACH1 (dachshund family transcription factor 1) [NCBI Gene 1602] {aka DACH}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, POU5F1 (POU class 5 homeobox 1) [NCBI Gene 5460] {aka OCT3, OCT4, OCT4Borf1, OTF-3, OTF3, OTF4}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, Fn1 (fibronectin 1) [NCBI Gene 14268] {aka E330027I09, Fn, Fn-1}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, CLDN25 (claudin 25) [NCBI Gene 644672], NANOG (Nanog homeobox) [NCBI Gene 79923], FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, CLDN11 (claudin 11) [NCBI Gene 5010] {aka HLD22, OSP, OTM}, AQP5 (aquaporin 5) [NCBI Gene 362] {aka AQP-5, PPKB}, SOX1 (SRY-box transcription factor 1) [NCBI Gene 6656], Jam3 (junction adhesion molecule 3) [NCBI Gene 83964] {aka 1110002N23Rik, JAM-3, JAM-C, Jcam3}, mucin [NCBI Gene 100508689], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, SOX2 (SRY-box transcription factor 2) [NCBI Gene 6657] {aka ANOP3, MCOPS3}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, Aqp4 (aquaporin 4) [NCBI Gene 11829] {aka WCH4}, Muc20 (mucin 20) [NCBI Gene 224116], AQP10 (aquaporin 10) [NCBI Gene 89872] {aka AQPA_HUMAN}, Abcb1b (ATP-binding cassette, sub-family B member 1B) [NCBI Gene 18669] {aka Abcb1, Mdr1, Mdr1b, Pgy-1, Pgy1, mdr}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, LIN28A (lin-28 RNA binding posttranscriptional regulator A) [NCBI Gene 79727] {aka CSDD1, LIN-28, LIN28, ZCCHC1, lin-28A}, SLC16A2 (solute carrier family 16 member 2) [NCBI Gene 6567] {aka AHDS, DXS128, DXS128E, MCT 7, MCT 8, MCT7}, ACTB (actin beta) [NCBI Gene 60] {aka BKRNS, BNS, BRWS1, CSMH, DDS1, PS1TP5BP1}, Muc1 (mucin 1, transmembrane) [NCBI Gene 17829] {aka CD227, EMA, Muc-1}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, SLC29A1 (solute carrier family 29 member 1 (Augustine blood group)) [NCBI Gene 2030] {aka AUG, ENT1, hENT1}, ABCB6 (ATP binding cassette subfamily B member 6 (LAN blood group)) [NCBI Gene 10058] {aka ABC, LAN, MTABC3, PRP, umat}, BLNK (B cell linker) [NCBI Gene 29760] {aka AGM4, BASH, BLNK-S, LY57, SLP-65, SLP65}, Cdh5 (cadherin 5) [NCBI Gene 12562] {aka 7B4, Cd144, VE-Cad, VECD, VEcad, Vec}, ABCG2 (ATP binding cassette subfamily G member 2 (JR blood group)) [NCBI Gene 9429] {aka ABC15, ABCP, BCRP, BMDP, CD338, CDw338}, OCLN (occludin) [NCBI Gene 100506658] {aka BLCPMG, PPP1R115, PTORCH1}, CLDN5 (claudin 5) [NCBI Gene 7122] {aka AWAL, BEC1, CPETRL1, TMDVCF, TMVCF}, LRP1 (LDL receptor related protein 1) [NCBI Gene 4035] {aka A2MR, APOER, APR, CD91, DDH3, IGFBP-3R}, Ocln (occludin) [NCBI Gene 18260] {aka Ocl}, Slc2a1 (solute carrier family 2 (facilitated glucose transporter), member 1) [NCBI Gene 20525] {aka GT1, Glut-1, Glut1, M100200, Rgsc200}, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) [NCBI Gene 28] {aka A3GALNT, A3GALT1, GTA, GTB, NAGAT}, Lsr (lipolysis stimulated lipoprotein receptor) [NCBI Gene 54135] {aka ILDR3, Lisch7}
- **Diseases:** HAL (MESH:D054975), psychotic disorders (MESH:D011618), amyloid (MESH:C000718787), insulin resistance (MESH:D007333), depression (MESH:D003866), AD (MESH:D000544), neuronal dysfunction (MESH:D009461), death (MESH:D003643), Cognitive Impairment (MESH:D003072), hypoxia (MESH:D000860), neurofibrillary tangles (MESH:D055956), HD (MESH:D006816), brain haemorrhaging (MESH:D020300), brain disease (MESH:D001927), impaired glucose (MESH:D044882), BBB dysfunction (MESH:C536830), MCI (MESH:D060825), Epstein-Barr virus infection (MESH:D020031), SCID I and II (MESH:D053632), inflammation (MESH:D007249), NPC (MESH:D052556), neuroinflammation (MESH:D000090862), Mental Disorders (MESH:D001523), neurodegeneration (MESH:D019636), dementia (MESH:D003704), DSM-IV (MESH:D006011), neurotoxic (MESH:D020258), cytotoxic (MESH:D064420), age- (MESH:D019588), vascular impairment (MESH:D020141), neurological disease (MESH:D020271)
- **Chemicals:** Hoechst 33342 (MESH:C017807), essential amino acids (MESH:D000601), Triton  X-100 (MESH:D017830), gentamycin (MESH:D005839), paraformaldehyde (MESH:C003043), sucrose (MESH:D013395), F12 (MESH:C007782), glycerol (MESH:D005990), Sodium fluorescein (MESH:D019793), cholesterol (MESH:D002784), CO2 (MESH:D002245), dibutyryl-cAMP (MESH:D003994), H2O (MESH:D014867), retinoic acid (MESH:D014212), cellulose acetate (MESH:C005062), HEPES (MESH:D006531), Y-27632 (MESH:C108830), N2 (MESH:D009584), poly-L-ornithine (MESH:C008973), Alexa Fluor  488 (MESH:C000711379), cytarabine (MESH:D003561), lipid (MESH:D008055), NaF (MESH:D012969), FC (MESH:C095424), cyclopamine (MESH:C000541), GlutaMAX (MESH:C054122), glucose (MESH:D005947), L-glutamine (MESH:D005973), CellTox (-), Florbetapir (MESH:C545186), peptides (MESH:D010455), L-ascorbic acid (MESH:D001205)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MT — Homo sapiens (Human), Transformed cell line (CVCL_2631), IMR90 — Homo sapiens (Human), Finite cell line (CVCL_0347), WISCi004-B — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_C437), LOAD — Homo sapiens (Human), Glycogen storage disease type II, Induced pluripotent stem cell (CVCL_0H84), CVCL_C437 — Homo sapiens (Human), Finite cell line (CVCL_X071), Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025), CVCL_UF44 — Homo sapiens (Human), Acute promyelocytic leukemia with PML-RARA, Cancer cell line (CVCL_0567), SH-SY5Y — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0019), BCECs — Homo sapiens (Human), Transformed cell line (CVCL_DQ72), ZIPi013-B — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_UF44), -4 — Homo sapiens (Human), Ataxia telangiectasia syndrome, Finite cell line (CVCL_F083)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12829042/full.md

---
Source: https://tomesphere.com/paper/PMC12829042